Show simple item record

dc.contributor.authorKaczmarek, Marlena C
dc.contributor.authorDuong, Uyen T
dc.contributor.authorWare, Robert S
dc.contributor.authorLambert, Stephen B
dc.contributor.authorKelly, Heath A
dc.date.accessioned2017-11-15T03:49:23Z
dc.date.available2017-11-15T03:49:23Z
dc.date.issued2013
dc.identifier.issn0264-410X
dc.identifier.doi10.1016/j.vaccine.2013.09.005
dc.identifier.urihttp://hdl.handle.net/10072/172364
dc.description.abstractThere are limited summary data published on the risk of fever and febrile seizures in children following influenza vaccination. We performed a review of the risk of fever and febrile seizures following receipt of trivalent inactivated influenza vaccine (TIV) in children aged ≥6 months to <36 months, searching PubMED and Google Scholar for English language articles from 2000 onwards, and initiated or ongoing unpublished studies since September 2007 using clinicaltrials.gov. Exclusions included other vaccine co-administration, missing ages or participant numbers, or unmeasured fever. We reviewed articles and collated results using a standard data extraction template. We identified a total of 909 published papers and unpublished trials from a search conducted on 23 January 2013, 669 from Google Scholar, 114 from PubMed and 126 from the Clinicaltrials.gov online database. After excluding 890 published papers or unpublished trials, 5 published papers and 14 unpublished trials were included in this review. Extracted data on number of events, children at risk and time of follow-up were converted to the risk of fever, which was averaged per week of follow-up (referred to as ‘averaged weekly risk’). Following one dose of TIV, the median averaged weekly risk of any fever (≥37.5 °C) was 26.0% (range 10.3–70.0%) in unpublished trials compared to 8.2% (range 5.3–28.3%) in published papers (p = 0.04). The median averaged weekly risk of severe fever (≥39.0 °C) was 3.2% (range 0–10.0%) and 2.0% (range 0.6–17.0%), respectively (p = 0.91). Variation in the reporting of fever by participant age groups, time since vaccination and the definition or measurement of fever resulted in a wide range of risk estimates. Reporting of febrile reactions should be standardised to allow comparison between manufacturers and influenza seasons.
dc.description.peerreviewedYes
dc.languageEnglish
dc.language.isoeng
dc.publisherElsevier
dc.relation.ispartofpagefrom5359
dc.relation.ispartofpageto5365
dc.relation.ispartofissue46
dc.relation.ispartofjournalVaccine
dc.relation.ispartofvolume31
dc.subject.fieldofresearchMicrobiology not elsewhere classified
dc.subject.fieldofresearchBiological Sciences
dc.subject.fieldofresearchAgricultural and Veterinary Sciences
dc.subject.fieldofresearchMedical and Health Sciences
dc.subject.fieldofresearchcode060599
dc.subject.fieldofresearchcode06
dc.subject.fieldofresearchcode07
dc.subject.fieldofresearchcode11
dc.titleThe risk of fever following one dose of trivalent inactivated influenza vaccine in children aged ≥6 months to <36 months: A comparison of published and unpublished studies
dc.typeJournal article
dc.type.descriptionC1 - Articles
dc.type.codeC - Journal Articles
gro.hasfulltextNo Full Text
gro.griffith.authorWare, Robert


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record